The Magnitude and Functionality of SARS-CoV-2 Reactive Cellular and Humoral Immunity in Transplant Population Is Similar to the General Population Despite Immunosuppression.
Journal
Transplantation
ISSN: 1534-6080
Titre abrégé: Transplantation
Pays: United States
ID NLM: 0132144
Informations de publication
Date de publication:
01 10 2021
01 10 2021
Historique:
pubmed:
15
5
2021
medline:
12
10
2021
entrez:
14
5
2021
Statut:
ppublish
Résumé
The ability of transplant (Tx) patients to generate a protective antiviral response under immunosuppression is pivotal in COVID-19 infection. However, analysis of immunity against SARS-CoV-2 is currently lacking. Here, we analyzed T cell immunity directed against SARS-CoV-2 spike-, membrane-, and nucleocapsid-protein by flow cytometry and spike-specific neutralizing antibodies in 10 Tx in comparison to 26 nonimmunosuppressed (non-Tx) COVID-19 patients. Tx patients (7 renal, 1 lung, and 2 combined pancreas-kidney Txs) were recruited in this study during the acute phase of COVID-19 with a median time after SARS-CoV-2-positivity of 3 and 4 d for non-Tx and Tx patients, respectively. Despite immunosuppression, we detected antiviral CD4+ T cell-response in 90% of Tx patients. SARS-CoV-2-reactive CD4+ T cells produced multiple proinflammatory cytokines, indicating their potential protective capacity. Neutralizing antibody titers did not differ between groups. SARS-CoV-2-reactive CD8+ T cells targeting membrane- and spike-protein were lower in Tx patients, albeit without statistical significance. However, frequencies of anti-nucleocapsid-protein-reactive, and anti-SARS-CoV-2 polyfunctional CD8+ T cells, were similar between patient cohorts. Tx patients showed features of a prematurely aged adaptive immune system, but equal frequencies of SARS-CoV-2-reactive memory T cells. In conclusion, a polyfunctional T cell immunity directed against SARS-CoV-2 proteins as well as neutralizing antibodies can be generated in Tx patients despite immunosuppression. In comparison to nonimmunosuppressed patients, no differences in humoral and cellular antiviral-immunity were found. Our data presenting the ability to generate SARS-CoV-2-specific immunity in immunosuppressed patients have implications for the handling of SARS-CoV-2-infected Tx patients and raise hopes for effective vaccination in this cohort.
Sections du résumé
BACKGROUND
The ability of transplant (Tx) patients to generate a protective antiviral response under immunosuppression is pivotal in COVID-19 infection. However, analysis of immunity against SARS-CoV-2 is currently lacking.
METHODS
Here, we analyzed T cell immunity directed against SARS-CoV-2 spike-, membrane-, and nucleocapsid-protein by flow cytometry and spike-specific neutralizing antibodies in 10 Tx in comparison to 26 nonimmunosuppressed (non-Tx) COVID-19 patients.
RESULTS
Tx patients (7 renal, 1 lung, and 2 combined pancreas-kidney Txs) were recruited in this study during the acute phase of COVID-19 with a median time after SARS-CoV-2-positivity of 3 and 4 d for non-Tx and Tx patients, respectively. Despite immunosuppression, we detected antiviral CD4+ T cell-response in 90% of Tx patients. SARS-CoV-2-reactive CD4+ T cells produced multiple proinflammatory cytokines, indicating their potential protective capacity. Neutralizing antibody titers did not differ between groups. SARS-CoV-2-reactive CD8+ T cells targeting membrane- and spike-protein were lower in Tx patients, albeit without statistical significance. However, frequencies of anti-nucleocapsid-protein-reactive, and anti-SARS-CoV-2 polyfunctional CD8+ T cells, were similar between patient cohorts. Tx patients showed features of a prematurely aged adaptive immune system, but equal frequencies of SARS-CoV-2-reactive memory T cells.
CONCLUSIONS
In conclusion, a polyfunctional T cell immunity directed against SARS-CoV-2 proteins as well as neutralizing antibodies can be generated in Tx patients despite immunosuppression. In comparison to nonimmunosuppressed patients, no differences in humoral and cellular antiviral-immunity were found. Our data presenting the ability to generate SARS-CoV-2-specific immunity in immunosuppressed patients have implications for the handling of SARS-CoV-2-infected Tx patients and raise hopes for effective vaccination in this cohort.
Identifiants
pubmed: 33988334
pii: 00007890-202110000-00011
doi: 10.1097/TP.0000000000003755
pmc: PMC8487706
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2156-2164Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Mohamed IH, Chowdary PB, Shetty S, et al. Outcomes of renal transplant recipients with SARS-CoV-2 infection in the eye of the storm: a comparative study with waitlisted patients. Transplantation. 2021;105:115–120.
Thieme CJ, Zgoura P, Todorova I, et al. COVID-19 associated risk score, behavior and symptom prevalence in German transplant recipients. Transplant Proc. 2020:S0041-1345(20)32897-9. doi: 10.1016/j.transproceed.2020.12.001
doi: 10.1016/j.transproceed.2020.12.001
Domínguez-Gil B, Fernández-Ruiz M, Hernández D, et al. Organ donation and transplantation during the COVID-19 pandemic: a summary of the Spanish experience. Transplantation. 2021;105:29–36.
Ritschl PV, Nevermann N, Wiering L, et al. Solid organ transplantation programs facing lack of empiric evidence in the COVID-19 pandemic: a By-proxy Society Recommendation Consensus approach. Am J Transplant. 2020;20:1826–1836.
Moal V, Zandotti C, Colson P. Emerging viral diseases in kidney transplant recipients. Rev Med Virol. 2013;23:50–69.
Azzi Y, Bartash R, Scalea J, et al. COVID-19 and solid organ transplantation: a review article. Transplantation. 2021;105:37–55.
Lai Q, Spoletini G, Bianco G, et al. SARS-CoV2 and immunosuppression: a double-edged sword. Transpl Infect Dis. 2020;22:e13404.
Minotti C, Tirelli F, Barbieri E, et al. How is immunosuppressive status affecting children and adults in SARS-CoV-2 infection? A systematic review. J Infect. 2020;81:e61–e66.
Babel N, Anft M, Blazquez-Navarro A, et al. Immune monitoring facilitates the clinical decision in multifocal COVID-19 of a pancreas-kidney transplant patient. Am J Transplant. 2020;20:3210–3215.
Akalin E, Azzi Y, Bartash R, et al. COVID-19 and kidney transplantation. N Engl J Med. 2020;382:2475–2477.
Pereira MR, Mohan S, Cohen DJ, et al. COVID-19 in solid organ transplant recipients: initial report from the US epicenter. Am J Transplant. 2020;20:1800–1808.
Zhang H, Chen Y, Yuan Q, et al. Identification of kidney transplant recipients with coronavirus disease 2019. Eur Urol. 2020;77:742–747.
Mamode N, Ahmed Z, Jones G, et al. Mortality rates in transplant recipients and transplantation candidates in a high-prevalence COVID-19 environment. Transplantation. 2021;105:212–215.
Ali T, Al-Ali A, Fajji L, et al. Coronavirus disease-19: disease severity and outcomes of solid organ transplant recipients: different spectrums of disease in different populations? Transplantation. 2021;105:121–127.
The RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with COVID-19 — preliminary report. N Engl J Med. 2020;384:693–704.
Pfefferle S, Schöpf J, Kögl M, et al. The SARS-coronavirus-host interactome: identification of cyclophilins as target for pan-coronavirus inhibitors. Plos Pathog. 2011;7:e1002331.
Kato F, Matsuyama S, Kawase M, et al. Antiviral activities of mycophenolic acid and IMD-0354 against SARS-CoV-2. Microbiol Immunol. 2020;64:635–639.
Cheng KW, Cheng SC, Chen WY, et al. Thiopurine analogs and mycophenolic acid synergistically inhibit the papain-like protease of Middle East respiratory syndrome coronavirus. Antiviral Res. 2015;115:9–16.
Fishman JA, Issa NC. Infection in organ transplantation: risk factors and evolving patterns of infection. Infect Dis Clin North Am. 2010;24:273–283.
López-Medrano F, Aguado JM, Lizasoain M, et al. Clinical implications of respiratory virus infections in solid organ transplant recipients: a prospective study. Transplantation. 2007;84:851–856.
Fischer SA. Emerging viruses in transplantation: there is more to infection after transplant than CMV and EBV. Transplantation. 2008;86:1327–1339.
Thieme CJ, Anft M, Paniskaki K, et al. Robust T cell response toward spike, membrane, and nucleocapsid SARS-CoV-2 proteins is not associated with recovery in critical COVID-19 patients. Cell Rep Med. 2020;1:100092.
Anft M, Paniskaki K, Blazquez-Navarro A, et al. COVID-19-induced ARDS is associated with decreased frequency of activated memory/effector T cells expressing CD11a+. Mol Ther. 2020;28:2691–2702.
R-Core-Team. R: A language and environment for statistical computing. Available at https://www.r-project.org . Accessed August 26, 2020.
Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506.
Betts MR, Nason MC, West SM, et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood. 2006;107:4781–4789.
Grifoni A, Weiskopf D, Ramirez SI, et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell. 2020;181:1489–1501.e15.
Sette A, Moutaftsi M, Moyron-Quiroz J, et al. Selective CD4+ T cell help for antibody responses to a large viral pathogen: deterministic linkage of specificities. Immunity. 2008;28:847–858.
Rydyznski Moderbacher C, Ramirez SI, Dan JM, et al. Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. Cell. 2020;183:996–1012.e19.
Bacher P, Rosati E, Esser D, et al. Low-avidity CD4+ T cell responses to SARS-CoV-2 in unexposed individuals and humans with severe COVID-19. Immunity. 2020;53:1258–1271.e5.
Grigoryev YA, Kurian SM, Avnur Z, et al. Deconvoluting post-transplant immunity: cell subset-specific mapping reveals pathways for activation and expansion of memory T, monocytes and B cells. PLoS One. 2010;5:e13358.
Betjes MG, Langerak AW, van der Spek A, et al. Premature aging of circulating T cells in patients with end-stage renal disease. Kidney Int. 2011;80:208–217.
Meijers RWJ, Litjens NHR, de Wit EA, et al. Uremia-associated immunological aging is stably imprinted in the T-cell system and not reversed by kidney transplantation. Transpl Int. 2014;27:1272–1284.
Segundo DS, Fernández-Fresnedo G, Gago M, et al. Changes in the number of circulating T CM and T em subsets in renal transplantation: relationship with acute rejection and induction therapy. Kidney Int Suppl. 2011;1:31–35.
Hirokawa K, Utsuyama M, Kikuchi Y, et al. Assessment of age-related decline of immunological function and possible methods for immunological restoration in elderly. In: Handbook on Immunosenescence. Springer; 2009:1547–1570.
Bae S, McAdams-DeMarco MA, Massie AB, et al. Early changes in kidney transplant immunosuppression regimens during the COVID-19 pandemic. Transplantation. 2021;105:170–176.
Avery RK. COVID-19 therapeutics for solid organ transplant recipients; 6 months into the pandemic: where are we now? Transplantation. 2021;105:56–60.
Weiss MJ, Lalani J, Patriquin-Stoner C, et al. Summary of international recommendations for donation and transplantation programs during the coronavirus disease pandemic. Transplantation. 2021;105:14–17.
Woodland DL, Blackman MA. Immunity and age: living in the past? Trends Immunol. 2006;27:303–307.
Benotmane I, Gautier-Vargas G, Wendling MJ, et al. In-depth virological assessment of kidney transplant recipients with COVID-19. Am J Transplant. 2020;20:3162–3172.
Candon S, Guerrot D, Drouot L, et al. T cell and antibody responses to SARS-CoV-2: experience from a French transplantation and hemodialysis center during the COVID-19 pandemic. Am J Transplant. 2021;21:854–863.
Rambal V, Müller K, Dang-Heine C, et al. Differential influenza H1N1-specific humoral and cellular response kinetics in kidney transplant patients. Med Microbiol Immunol. 2014;203:35–45.
Bunde T, Kirchner A, Hoffmeister B, et al. Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells. J Exp Med. 2005;201:1031–1036.
Weist BJ, Wehler P, El Ahmad L, et al. A revised strategy for monitoring BKV-specific cellular immunity in kidney transplant patients. Kidney Int. 2015;88:1293–1303.
Stock PG, Wall A, Gardner J, et al.; TTS Ethics Committee. Ethical issues in the COVID era: doing the right thing depends on location, resources, and disease burden. Transplantation. 2020;104:1316–1320.